Ischemic stroke: treatment on the horizon.
Giroux
C
C
Synthélabo Recherche, Bagneux, France.
Scatton
B
B
D001925:Brain Damage, Chronic / Q000503:physiopathology / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015220:Calcium Channels / Q000502:physiology; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016166:Free Radical Scavengers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D017382:Reactive Oxygen Species / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D018691:Excitatory Amino Acid Antagonists; D016166:Free Radical Scavengers; D017382:Reactive Oxygen Species; D016194:Receptors, N-Methyl-D-Aspartate